Background: A subpopulation of Pseudomonas aeruginosa (PsA) exists in cysticfibrosis (CF) patients that is hypersusceptible to ticarcillin, a carboxypenicillin, in vitro (Tichs strain) defined as a minimum inhibitory concentration (MIC) ≤4μg/ml. Methods: In a retrospective cohort study, isolates of PsA from CF (23), non-cystic fibrosis bronchiectasis (NCFB) (17) and control (18) patients were analysed. MICs for each isolate were determined using agar dilution against six antibiotics and interpreted using EUCAST breakpoints. Prevalence of Tichs in each cohort was calculated. A point prevalence survey was conducted in CF to review the patients’ clinical progress following PsA isolatio
Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity...
Respiratory failure secondary to chronic bronchiectasis is the cause of death in more than 90% of pa...
Prior to modern typing methods, cross-infection of P. aeruginosa between people with cystic fibrosis...
Background: A subpopulation of Pseudomonas aeruginosa (PsA) exists in cysticfibrosis (CF) patients t...
International audienceRetrospective analysis of 189 non redundant strains of Pseudomonas aeruginosa ...
Abstract Background and Objective: Cystic fibrosis (CF) is an autosomal recessive genetic disease a...
Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis patients. This...
Its rising incidence, virulence factors and antibiotic resistance rate makes it difficult to treat P...
Objectives: To evaluate the effect of antibiotic combination therapy versus single therapy against c...
Objectives: To test the presumption that Pseudomonas aeruginosa isolates responsible for initial lun...
Introduction: Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is an important and growing issue ...
The major cause of death in CF is a continuous inflammation of the lungs colonised with Pseudomonas ...
Background: Pseudomonas aeruginosa is one of the primary pathogens being isolated more frequently in...
Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity...
ObjectiveDetermination of the extent of changes in quantitative resistance in Pseudomonas aeruginosa...
Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity...
Respiratory failure secondary to chronic bronchiectasis is the cause of death in more than 90% of pa...
Prior to modern typing methods, cross-infection of P. aeruginosa between people with cystic fibrosis...
Background: A subpopulation of Pseudomonas aeruginosa (PsA) exists in cysticfibrosis (CF) patients t...
International audienceRetrospective analysis of 189 non redundant strains of Pseudomonas aeruginosa ...
Abstract Background and Objective: Cystic fibrosis (CF) is an autosomal recessive genetic disease a...
Pseudomonas aeruginosa is a major cause of morbidity and mortality in cystic fibrosis patients. This...
Its rising incidence, virulence factors and antibiotic resistance rate makes it difficult to treat P...
Objectives: To evaluate the effect of antibiotic combination therapy versus single therapy against c...
Objectives: To test the presumption that Pseudomonas aeruginosa isolates responsible for initial lun...
Introduction: Multidrug-resistant Pseudomonas aeruginosa (MDR-PA) is an important and growing issue ...
The major cause of death in CF is a continuous inflammation of the lungs colonised with Pseudomonas ...
Background: Pseudomonas aeruginosa is one of the primary pathogens being isolated more frequently in...
Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity...
ObjectiveDetermination of the extent of changes in quantitative resistance in Pseudomonas aeruginosa...
Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity...
Respiratory failure secondary to chronic bronchiectasis is the cause of death in more than 90% of pa...
Prior to modern typing methods, cross-infection of P. aeruginosa between people with cystic fibrosis...